

List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6901110/alberta-y-hoi-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52 papers	1,444 citations	20 h-index	37 g-index
61 ext. papers	1,955 ext. citations	5.9 avg, IF	4.61 L-index

#	Paper	IF	Citations
52	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1615-21	2.4	235
51	Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. <i>Journal of Immunology</i> , <b>2006</b> , 177, 5687-96	5.3	111
50	Clinical associations of serum interleukin-17 in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R97	5.7	101
49	TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 291-8	15.5	91
48	Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 3219-25	9.5	78
47	Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. <i>Inflammation and Allergy: Drug Targets</i> , <b>2007</b> , 6, 183-90		74
46	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. <i>Lupus</i> , <b>2013</b> , 22, 873-84	2.6	62
45	Analysis of Serum Interleukin (IL)-1 $\beta$ and IL-18 in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1250	8.4	57
44	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2016</b> , 6, 34604	4.9	53
43	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000157	4.6	53
42	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. <i>Lupus</i> , <b>2013</b> , 22, 1425-30	2.6	49
41	Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000064	4.6	45
40	Discordance of patient and physician health status concerns in systemic lupus erythematosus. <i>Lupus</i> , <b>2018</b> , 27, 501-506	2.6	35
39	The need to define treatment goals for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 567-71	8.1	33
38	Global epidemiology of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 515-532	8.1	29
37	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , <b>2019</b> , 1, e95-e102	14.2	26
36	Systemic lupus erythematosus: an update. <i>Medical Journal of Australia</i> , <b>2017</b> , 206, 215-220	4	23

35	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e24-e30	14.2	22
34	Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , <b>2019</b> , 8, e01093	6.8	22
33	Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000212	4.6	20
32	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. <i>Lancet Rheumatology, The</i> , <b>2019</b> , 1, e103-e110	14.2	19
31	Asian ethnicity in systemic lupus erythematosus: an Australian perspective. <i>Internal Medicine Journal</i> , <b>2013</b> , 43, 618-24	1.6	18
30	Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?. <i>Immunology and Cell Biology</i> , <b>2003</b> , 81, 367-73	5	17
29	Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , <b>2019</b> , 8, e01047	6.8	15
28	Abatacept in the treatment of lupus. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1399-406	5.4	15
27	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 425-433	2.3	14
26	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1289-1295	4.7	12
25	Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis. <i>Clinical and Translational Immunology</i> , <b>2018</b> , 7, e1042	6.8	11
24	The Australian Lupus Registry and Biobank: a timely initiative. <i>Medical Journal of Australia</i> , <b>2017</b> , 206, 194-195	4	10
23	Is there still a role for abatacept in the treatment of lupus?. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 1345-50	5.4	10
22	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 1255-1257	2.3	9
21	Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000277	4.6	8
20	Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000105	4.6	7
19	Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	7
18	Asian lupus in a multi-ethnic society: what can be learnt?. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 113-6	2.3	7

17	A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , <b>2019</b> , 8, e01097	6.8	7
16	The Rare Anaphylaxis-Associated FcγRIIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIIa1. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1809	8.4	7
15	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	6
14	Algorithm for calculating high disease activity in SLE. <i>Rheumatology</i> , <b>2021</b> , 60, 4291-4297	3.9	5
13	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 271-278	4.1	3
12	Trimethoprim-induced aseptic meningitis: a reminder case review. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 664-665	2.3	3
11	Associations of metabolic syndrome in SLE. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	3
10	Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1649	8.4	2
9	Granulocyte colony-stimulating factor is not pathogenic in lupus nephritis. <i>Immunity, Inflammation and Disease</i> , <b>2021</b> , 9, 758-770	2.4	2
8	Treatment Update in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2021</b> , 47, 513-530	2.4	2
7	The art of managing medical uncertainty. <i>Lancet, The</i> , <b>2016</b> , 387, 1026	4.0	2
6	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , <b>2021</b> , 60, 5185-5193	3.9	1
5	Not at target prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 70	5.7	1
4	Cytokines: Their Role in Amplifying SLE Pathogenesis <b>2021</b> , 109-131		
3	Disease course following High Disease Activity Status revealed patterns in SLE. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 191	5.7	
2	Purtscher-like retinopathy in anti-MDA5 dermatomyositis: a window to underlying microvasculopathy. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 473-474	2.2	
1	Purtscher-like retinopathy in anti-MDA5 dermatomyositis: a window to underlying microvasculopathy.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> ,	2.2	